癌症相关静脉血栓栓塞延长抗凝期间临床相关出血的预测因素(API-CAT):一项随机非劣效性试验的事后分析
API-CAT随机双盲非劣效性试验的事后分析,纳入1766例活动性癌症伴急性近端深静脉血栓或肺栓塞、已完成≥6个月抗凝的患者,随机接受阿哌沙班5.0 mg或2.5 mg每日两次口服12个月。12个月内238例发生临床相关出血;总体人群中贫血和/或血小板减少、年龄≥75岁、肺栓塞为索引事件及男性与临床相关出血风险升高显著相关,各 predictor 与剂量方案间无显著交互作用。
要点
- 贫血和/或血小板减少者临床相关出血风险升高(亚分布HR 1.93,95%CI 1.27-2.95)。
- 年龄≥75岁、肺栓塞为索引事件、男性亦与临床相关出血风险升高显著相关。
- 上述预测因素在各癌症部位间结果一致,与阿哌沙班剂量方案无显著交互作用。
核心结论
- 在癌症相关静脉血栓栓塞延长治疗期间,总体人群中识别出四个临床相关出血预测因素,且无证据显示其与给药方案存在交互作用。
- 作者认为,虽然API-CAT研究并非专门针对抗凝终止而设计,但这些发现可能有助于临床医生更有效地权衡延长抗凝治疗的获益与风险。
研究设计与样本
- API-CAT为在11个国家121家医院开展的随机、双盲、非劣效性试验,事后分析在意向治疗人群中进行。
- 纳入年龄>18岁、组织学诊断的活动性癌症(除外皮肤基底细胞癌或鳞状细胞癌、原发性脑肿瘤或脑内转移)且伴急性近端深静脉血栓或肺栓塞、已完成≥6个月抗凝、ECOG体能状态0-2分的患者。
- 2018年10月11日至2023年9月6日共1766例患者被随机分配至减剂量组(n=866)或全剂量组(n=900),按1:1接受阿哌沙班5.0 mg或2.5 mg每日两次口服12个月。
- 采用多变量竞争风险回归模型,以临床相关出血为因变量并校正阿哌沙班剂量,关联以亚分布风险比(HR)及95%CI表示,p<0.05视为有统计学显著性。
主要发现
- 中位随访12.9个月(IQR 11.8-13.2);1766例中男性766例(43.4%)、女性1000例(56.6%)。
- 12个月时238例患者发生临床相关出血。
- 总体人群中,贫血和/或血小板减少(亚分布HR 1.93 [95%CI 1.27-2.95])、年龄≥75岁(1.51 [1.14-2.02])、肺栓塞为索引事件(1.47 [1.03-2.10])及男性(1.38 [1.05-1.82])与临床相关出血风险升高显著相关。
- 上述结果在各癌症部位间一致,剂量方案与任一预测因素间均无统计学显著交互作用(所有p交互>0.30)。
关键数值与推荐
- 贫血和/或血小板减少:亚分布HR 1.93(95%CI 1.27-2.95)。
- 年龄≥75岁:亚分布HR 1.51(95%CI 1.14-2.02)。
- 肺栓塞为索引事件:亚分布HR 1.47(95%CI 1.03-2.10)。
- 男性:亚分布HR 1.38(95%CI 1.05-1.82)。
- 剂量方案与任一预测因素的交互作用检验均p>0.30。
临床怎么用
- 作者认为这些发现可能有助于临床医生更有效地权衡延长抗凝治疗的获益与风险。
- 原文未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Extended anticoagulation with reduced-dose apixaban was shown to be non-inferior to full-dose apixaban for preventing recurrent venous thromboembolism (VTE) in patients with active cancer and to be associated with fewer clinically relevant bleeding complications in a non-inferiority trial. In this post-hoc analysis, we sought to identify predictors associated with clinically relevant bleeding. METHODS: API-CAT was a randomised, double-blind, non-inferiority trial done in 121 hospitals in 11 countries. Eligible patients were adults older than 18 years, with active cancer diagnosed histologically (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumour, or intra-cerebral metastasis) and acute proximal deep-vein thrombosis or pulmonary embolism, 6 months or more of completed anticoagulation, and an Eastern Cooperative Oncology Group performance status of 0-2. Patients were centrally randomly assigned (1:1) to apixaban 5·0 mg or 2·5 mg twice daily orally for 12 months using an interactive web-response system, and stratified by trial centre, index event, and cancer site. The primary endpoint, reported previously, was the centrally adjudicated fatal or non-fatal recurrent venous thromboembolism. The primary objective for this post-hoc analysis was to identify predictors of clinically relevant bleeding during extended therapy in the overall population and to evaluate how these predictors vary according to cancer type. The post hoc-analysis was done in the intention-to-treat population, multivariable competing-risks regression model was built with clinically relevant bleeding as the dependent variable and was adjusted for apixaban dose. The association between potential predictors and clinically relevant bleeding was expressed as subdistribution hazard ratio (HR) with 95% CIs. Variables with a p value less than 0·05 were considered statistically significant associated with clinically relevant bleeding. The trial is registered with ClinicalTrials.gov (NCT03692065) and is complete. FINDINGS: Between Oct 11, 2018, and Sept 6, 2023, 1766 patients were randomly assigned to the reduced-dose group (n=866) or the full-dose group (n=900). Median follow-up was 12·9 months (IQR 11·8-13·2). 766 (43·4%) of 1766 patients were male and 1000 (56·6%) were female. At 12 months, clinically relevant bleeding occurred in 238 patients. In the overall population, anaemia and/or thrombocytopenia (subdistribution HR 1·93 [95% CI 1·27-2·95]), age 75 years or older (1·51 [1·14-2·02]), pulmonary embolism as the index event (1·47 [1·03-2·10]), and male sex (1·38 [1·05-1·82]) were significantly associated with an increased risk of clinically relevant bleeding. These results are homogeneous across cancer sites, with no evidence of statistically significant interaction between dose regimen and any predictor (all pinteraction>0·30). INTERPRETATION: During extended treatment for cancer-associated VTE, four predictors of clinically relevant bleeding were identified in the overall population, with no evidence of interaction with the dosing regimen. Although the API-CAT study was not designed to specifically address anticoagulation discontinuation, our findings might help clinicians to more effectively balance the benefits and risks of extended anticoagulant therapy. FUNDING: None.
引用
- Mahé I, Chapelle C, Girard P, et al. Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial. Lancet Haematol. 2025. PMID: 41365312. doi:10.1016/S2352-3026(25)00291-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。